1,002 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Bingham Private Wealth LLC

Bingham Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,002 shares of the medical research company’s stock, valued at approximately $581,000.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Cornerstone Investment Partners LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth $41,393,000. Weaver Capital Management LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth $506,000. Mackenzie Financial Corp increased its position in Thermo Fisher Scientific by 29.4% during the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after buying an additional 62,790 shares during the last quarter. VELA Investment Management LLC increased its position in Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company’s stock worth $4,513,000 after buying an additional 3,683 shares during the last quarter. Finally, NEOS Investment Management LLC increased its position in Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock worth $24,913,000 after buying an additional 11,415 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 2.5%

Shares of NYSE:TMO opened at $527.26 on Wednesday. The company has a market cap of $195.94 billion, a P/E ratio of 29.72, a P/E/G ratio of 2.75 and a beta of 0.97. The stock’s 50-day moving average is $503.14 and its 200-day moving average is $550.25. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business posted $6.10 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a $0.47 dividend. The ex-dividend date is Friday, March 13th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 10.60%.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Zacks and Yahoo analyses highlight Thermo Fisher as one of a small group of medical stocks likely to beat upcoming quarterly earnings (strong earnings-surprise history and favorable Earnings ESP), which can drive upside on an earnings beat. These 2 Medical Stocks Could Beat Earnings
• Positive Sentiment: Thermo Fisher’s PPD clinical research unit announced a strategic collaboration with HealthVerity to expand real‑world data capabilities — a revenue-accretive move that strengthens its clinical services offering and makes future contract wins more likely. Thermo Fisher PPD Clinical Research Collaborates with HealthVerity
• Positive Sentiment: Industry reports project strong growth in allergy diagnostics and small‑molecule CDMO markets through 2030–2033 and list Thermo Fisher as a leading participant — reinforcing a favorable long‑term demand outlook for its diagnostics and CDMO businesses. Allergy Diagnostic Market Forecast Small Molecule Innovator API CDMO Market Outlook
• Neutral Sentiment: Barclays cut its TMO price target from $650 to $625 but maintained an “Overweight” rating — a mild trimming of upside expectation but still institutional support for the stock. Barclays Lowers Price Target to $625
• Neutral Sentiment: Recent valuation commentary notes short‑term share volatility (mixed 1‑, 3‑month returns) — useful context for traders but not a direct fundamental change. Valuation and Volatility Analysis

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 target price on the stock. Stifel Nicolaus increased their target price on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Evercore reissued an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $631.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.